Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 11/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6574331 | 0.91 | F2 (0.42) | F2KEAP1NFE2L2MLYCDOXTR | |
| SCHEMBL6571764 | 0.77 | HCRTR2 (0.43) | KEAP1NFE2L2MLYCDOXTR | |
| Hydrochloric Acid SCHEMBL7354708 | 0.77 | F2 (0.48) | F2KEAP1NFE2L2OXTRPRSS1 | |
| SCHEMBL6978671 | 0.75 | F2 (0.46) | F2KEAP1NFE2L2 | |
| SCHEMBL6765970 | 0.74 | F2 (0.47) | F2KEAP1NFE2L2PRSS1PRSS2 | |
| SCHEMBL6978680 | 0.72 | KEAP1 (0.47) | F2KEAP1NFE2L2SLC16A3PRSS1 | |
| Hydrochloric Acid SCHEMBL7351983 | 0.70 | F2 (0.48) | F2KEAP1NFE2L2OXTR | |
| Hydrochloric Acid SCHEMBL6979622 | 0.70 | F2 (0.39) | F2PRSS1 | |
| SCHEMBL6570643 | 0.68 | F2 (0.45) | F2PRSS1PRSS2PRSS3 | |
| SCHEMBL7956920 | 0.68 | F2 (0.46) | F2KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248897-A1 | Substituted N-acylaniline derivatives, the preparation thereof, and their use as pharmaceutical compositions | NAT1, CYP3A5, CYP3A7 | F2 612/4885KEAP1 3010/4885NFE2L2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.